Targeting cancer with power and precision

Sesen Bio, Inc. (NASDAQ: SESN), previously Eleven Biotherapeutics, Inc., is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer. Their approach aims to overcome limitations of traditional ADCs by incorporating a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively, effectively and broadly kill cancer cells while sparing healthy cells. These single protein molecules are known as fusion proteins. Their lead program, Vicinium™, is a novel fusion protein currently in Phase 3 development for the treatment of patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin (BCG).

Year Invested: 2010
Location: Cambridge, Mass.

Recent News

December 3, 2018
Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer

November 8, 2018
Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts

September 20, 2018
Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018

Read More News

Associated Team Members

Cary Pfeffer, M.D.

Abbie Celniker, Ph.D.